SCHEMBL2943933

SCHEMBL2943933

CC(C)(C)c1cc(NC(=O)Nc2ccc(O)cc2)no1

nearest known ligand 0.78

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 3/20 0.78
MEN1 O00255 1/20 0.77
NPC1 O15118 1/20 0.77
RAB9A P51151 1/20 0.77
KMT2A Q03164 1/20 0.77
FLT3 P36888 8/20 0.70
RAF1 P04049 7/20 0.69
MAPK13 O15264 1/20 0.69
MAPK12 P53778 1/20 0.69
MAPK11 Q15759 1/20 0.69
RIPK2 O43353 1/20 0.67
KDR P35968 1/20 0.66
CSF1R P07333 1/20 0.65
RET P07949 1/20 0.65
PDGFRB P09619 1/20 0.65
KIT P10721 1/20 0.65
PDGFRA P16234 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13234368 0.96 MAPK14 (0.72) MAPK14MEN1NPC1RAB9AKMT2A
SCHEMBL668361 0.92 RAF1 (0.82) MAPK14MEN1NPC1RAB9AKMT2A
SCHEMBL13234435 0.89 MAPK14 (0.78) MAPK14MEN1NPC1RAB9AKMT2A
SCHEMBL13234418 0.89 MAPK14 (0.78) MAPK14MEN1NPC1RAB9AKMT2A
SCHEMBL13234666 0.89 MAPK14 (0.78) MAPK14MEN1NPC1RAB9AKMT2A
SCHEMBL13234430 0.87 MAPK14 (0.76) MAPK14MEN1NPC1RAB9AKMT2A
SCHEMBL13234448 0.87 MAPK14 (1.00) MAPK14MEN1NPC1RAB9AKMT2A
SCHEMBL13264366 0.87 MAPK14 (0.76) MAPK14MEN1NPC1RAB9AKMT2A
SCHEMBL1698822 0.87 MAPK14 (0.76) MAPK14MEN1NPC1RAB9AKMT2A
SCHEMBL1255104 0.87 MAPK14 (0.78) MAPK14MEN1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100173917-A1 UREA DERIVATIVES AS ABL MODULATORS AMBIT BIOSCIENCES CORPORATION 2010-07-08 US disclosed
US-20100173917-A1 UREA DERIVATIVES AS ABL MODULATORS AMBIT BIOSCIENCES CORPORATION 2010-07-08 US disclosed
US-20100173917-A1 UREA DERIVATIVES AS ABL MODULATORS AMBIT BIOSCIENCES CORPORATION 2010-07-08 US disclosed
US-7750160-B2 Isoxazolyl urea derivatives as kinase modulators AMBIT BIOSCIENCES CORPORATION (US) 2010-07-06 US disclosed
US-7750160-B2 Isoxazolyl urea derivatives as kinase modulators AMBIT BIOSCIENCES CORPORATION (US) 2010-07-06 US disclosed
US-7750160-B2 Isoxazolyl urea derivatives as kinase modulators AMBIT BIOSCIENCES CORPORATION (US) 2010-07-06 US disclosed
EP-1684762-A4 UREA DERIVATIVES AS KINASE MODULATORS AMBIT BIOSCIENCES CORP (US) 2009-06-17 EP disclosed
EP-1684762-A2 UREA DERIVATIVES AS KINASE MODULATORS Ambit Biosciences Corporation (US) 2006-08-02 EP disclosed
US-20050267182-A1 Urea derivatives as FLT-3 modulators AMBIT BIOSCIENCES CORPORATION 2005-12-01 US disclosed
US-20050197371-A1 Urea derivatives as PDGFR modulators AMBIT BIOSCIENCES CORPORATION 2005-09-08 US disclosed
US-20050192314-A1 Urea derivatives as C-kit modulators AMBIT BIOSCIENCES CORPORATION 2005-09-01 US disclosed
US-20050165031-A1 Urea derivatives as ABL modulators AMBIT BIOSCIENCES CORPORATION 2005-07-28 US disclosed
US-20050165024-A1 Urea derivatives as kinase modulators AMBIT BIOSCIENCES CORPORATION 2005-07-28 US disclosed
WO-2005048948-A2 UREA DERIVATIVES AS KINASE MODULATORS AMBIT BIOSCIENCES CORPORATION (US) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165024-A1 Urea derivatives as kinase modulators ULK2, ULK1, ULK3 MAPK14 231/4885MEN1 4259/4885NPC1 1503/4885
US-20100173917-A1 UREA DERIVATIVES AS ABL MODULATORS ABL1, ABL2, BCR MAPK14 1436/4885MEN1 4362/4885NPC1 1569/4885
US-20050192314-A1 Urea derivatives as C-kit modulators KIT, PRKCH, PRKCE MAPK14 481/4885MEN1 2079/4885NPC1 1943/4885
US-20050267182-A1 Urea derivatives as FLT-3 modulators FLT4, FLT1, FLT3 MAPK14 1779/4885MEN1 3423/4885NPC1 3228/4885
US-20050197371-A1 Urea derivatives as PDGFR modulators PDGFRA, PDGFRB, PDGFA MAPK14 1909/4885MEN1 4597/4885NPC1 2160/4885
US-20050165031-A1 Urea derivatives as ABL modulators ABL1, ABL2, BCR MAPK14 1436/4885MEN1 4362/4885NPC1 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.